NCT07618988已完成4 期
Safety and Efficacy of Rivaroxaban in Pediatric Patients With Deep Venous Thrombosis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
详细描述
Treatment of deep venous thrombotic events in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. Rivaroxaban is a direct oral anticoagulant which has been approved by FDA in 2021 for the use in pediatric patients with venous thrombosis.
In a randomized controlled trial we will study the safety and efficacy of rivaroxaban use in the pediatric population with acute deep venous thrombosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients from 6 months to less than 18 years of age.
- •Patients with acute deep venous thrombosis diagnosed based on site-appropriate imaging tools e.g., magnetic resonance venography (MRV) in Cerebral sinus venous thrombosis (CSVT), venous duplex in Central Venous Access Devices (CVAD) related thrombosis or other non-CSVT DVT.
- •Patients with cancer associated thrombosis are eligible.
- •Patients with provoked or unprovoked acute VT are eligible.
- •Patients with first thrombotic event or recurrent VT are eligible.
排除标准
- •Patients with active bleeding
- •High-risk of bleeding including:
- •Platelet count of less than 50 x 109/L,
- •Liver disease associated either a coagulopathy leading to a clinically relevant bleeding risk, or ALT > 5× ULN.
- •Sustained uncontrolled hypertension defined as systolic and/or diastolic blood pressure > 95th age percentile.
- •Severe renal impairment (Estimated glomerular filtration rate < 30 mL/min/1.73m2).
- •Gastrointestinal disease associated with impaired absorption.
- •Hypersensitivity or any other contraindication listed in the local labelling for Rivaroxaban or comparator treatment.
- •Patients with rheumatic heart disease or prosthetic heart valves.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaNCT07495631Institute of Hematology & Blood Diseases Hospital, China43
招募中
4 期
Rivaroxaban in Idiopathic Membranous NephropathyNCT07404436Beijing Friendship Hospital134
已完成
不适用
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous ThrombosisCerebrosinovenous ThrombosisNCT07523347Muhammad Aamir Latif75
尚未招募
不适用
Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic SyndromeFRNS/SDNSRipertamabNCT07388810Mao Jianhua312
尚未招募
3 期
A study to estimate the Efficiency and Safety of Lumateperone as treatment used for irritation related to Autism Spectrum Disorder in Childrens aged 5 to 17 Years.CTRI/2025/11/097254Intra-Cellular Therapies, Inc.174